Accelerating Efficacious & Safer Bispecific, Trispecific, & Multispecifics

The bispecific and multispecific antibody field is advancing rapidly, fuelled by strong clinical readouts, growing biopharma investment, and increasingly sophisticated antibody designs. As programs evolve beyond first-generation bispecifics toward trispecific and multispecific strategies, the industry is sharpening its focus on improving efficacy while expanding the therapeutic window through improved safety and toxicity profiles.

With an increasing number of bispecifics progressing toward the clinic, the inaugural World Bispecific Summit Europe brings Europe’s bispecific leaders together for the first time, building on the proven success of the World Bispecific Summit US. This industry-led forum delivers deep technical discussions and case studies spanning novel antibody formats, next-generation TCEs, and bispecific ADCs, accelerating bispecifics from bench to clinic through conditional activation strategies, co-stimulation, and translational insights.

With clinical momentum accelerating and unresolved challenges still to solve, now is the time to connect, collaborate, and shape the future of bispecific therapies. Join a high-calibre community in London, July 2026, and be part of the next wave of precision-driven care.